Nicole J Gormley

12PUBLICATIONS
116CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumoursMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.

Jennifer J Gao, Tatiana M Prowell, Haley Gittleman

|May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Mirat Shah, Ting-Yu Chen, Gwynn Ison

|Oct 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.

Andrea C Baines, Bindu Kanapuru, Jay Zhao

|Oct 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.

Maryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu

|Jul 22, 2024
Improving Collection and Analysis of Overall Survival Data.

Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu

|Mar 05, 2024
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.

Irene M Ghobrial, Nicole Gormley, Shaji K Kumar

Pageof 2

Frequent Collaborators

8 joint publications

Marc Theoret

8 joint publications

Richard Pazdur

4 joint publications

Laleh Amiri-Kordestani

4 joint publications

Nicholas C Richardson